Viewing stories from January, 2013

30 January 2013
Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 31 December 2012.

Read More

6 January 2013
Herald Sun: Promising shares for the adventurous investor - Small can be bountiful

The Herald Sun’s Chief Business Writer John Beveridge investigates some of the best strategies to make money on the stock market and profiles Starpharma as having potential, following the results of its Phase III trial for VivaGel as a treatment for BV:

All is not lost, though, because VivaGel still has potential to become the most effective treatment for the complaint and the company's dendrimer technology has numerous other lucrative applications.

Read More

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.